ERTAPENEM SODIUM Drug Patent Profile

Which patents cover Ertapenem Sodium, and when can generic versions of Ertapenem Sodium launch?

Ertapenem Sodium is a drug marketed by Acs Dobfar Spa, Eugia Pharma, Gland, Qilu Antibiotics, Savior Lifetec Corp, and Sun Pharm. and is included in six NDAs.

The generic ingredient in ERTAPENEM SODIUM is ertapenem sodium. There are eight drug master file entries for this compound. Seventeen suppliers are listed for this compound. Additional details are available on the ertapenem sodium profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Ertapenem Sodium

A generic version of ERTAPENEM SODIUM was approved as ertapenem sodium by ACS DOBFAR SPA on April 16^th, 2018.

Summary for ERTAPENEM SODIUM

US Patents:	0
Applicants:	6
NDAs:	6

Paragraph IV (Patent) Challenges for ERTAPENEM SODIUM

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
INVANZ	Injection	ertapenem sodium	1 g/vial	021337	1	2012-12-21

US Patents and Regulatory Information for ERTAPENEM SODIUM

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Acs Dobfar Spa	ERTAPENEM SODIUM	ertapenem sodium	INJECTABLE;INTRAMUSCULAR, INTRAVENOUS	208790-001	Apr 16, 2018	AP	RX	No	No
Qilu Antibiotics	ERTAPENEM SODIUM	ertapenem sodium	INJECTABLE;INTRAMUSCULAR, INTRAVENOUS	218067-001	Oct 31, 2024	AP	RX	No	No
Eugia Pharma	ERTAPENEM SODIUM	ertapenem sodium	INJECTABLE;INTRAMUSCULAR, INTRAVENOUS	209133-001	Jun 25, 2018	AP	RX	No	No

ERTAPENEM SODIUM: INVESTMENT AND FUNDAMENTALS ANALYSIS

Last updated: February 19, 2026

Executive Summary

Ertapenem sodium, a carbapenem antibiotic, presents a mature market with established efficacy and a history of patent challenges. Its primary therapeutic role is in treating moderate to severe infections caused by susceptible anaerobic and aerobic gram-positive and gram-negative bacteria. The drug's market dynamics are influenced by generic competition, evolving resistance patterns, and the ongoing need for broad-spectrum antibiotics. This analysis assesses the investment landscape and fundamental strengths of ertapenem sodium, focusing on its patent status, market penetration, and future prospects.

What is Ertapenem Sodium's Patent Landscape?

Ertapenem sodium was originally patented by Merck & Co., Inc. The U.S. Patent No. 5,677,292, titled "Carbapenem compounds and process for their preparation," was granted on October 14, 1997. This patent covered ertapenem and its salts, including ertapenem sodium. The primary period of patent exclusivity for the original compound has expired, allowing for generic market entry.

Subsequent patents and patent applications related to ertapenem have focused on specific aspects such as:

• Formulations: Novel delivery systems, extended-release formulations, or specific salt forms that could offer improved stability or pharmacokinetic profiles. For example, U.S. Patent No. 7,407,959, "Ertapenem formulation," filed by Merck, aimed to improve ertapenem compositions.
• Manufacturing Processes: Improvements or novel methods for synthesizing ertapenem, which can be critical for generic manufacturers to circumvent existing process patents or achieve cost efficiencies.
• Methods of Use: Specific indications or treatment regimens for ertapenem, although these are often more challenging to defend against generic development for broad-spectrum antibiotics.

The expiration of key composition-of-matter patents has led to significant generic competition. However, companies may still hold patents on specific manufacturing routes or advanced formulations that could provide limited market advantages or act as barriers to entry for some competitors. The ongoing litigation surrounding these secondary patents often dictates the pace and breadth of generic market penetration.

What are Ertapenem Sodium's Primary Therapeutic Indications and Mechanisms of Action?

Ertapenem sodium is a carbapenem antibiotic used for the treatment of moderate to severe infections. Its broad spectrum of activity makes it effective against a wide range of aerobic and anaerobic bacteria, including many gram-positive and gram-negative organisms.

Key indications include:

• Complicated intra-abdominal infections: Infections involving the peritoneum, gallbladder, liver, and other intra-abdominal organs.
• Complicated skin and skin structure infections: Including diabetic foot infections and cellulitis caused by susceptible bacteria.
• Community-acquired pneumonia: Moderate to severe cases where bacterial resistance is a concern.
• Complicated urinary tract infections: Including pyelonephritis.
• Pelvic inflammatory disease: Including tubo-ovarian abscess.

Mechanism of Action:

Ertapenem, like other carbapenems, inhibits bacterial cell wall synthesis. It binds to penicillin-binding proteins (PBPs), which are essential enzymes involved in the cross-linking of peptidoglycan. By inactivating these PBPs, ertapenem prevents the formation of a stable and intact bacterial cell wall. This disruption leads to bacterial lysis and cell death. Ertapenem is relatively stable against hydrolysis by most beta-lactamases, including many extended-spectrum beta-lactamases (ESBLs) and AmpC beta-lactamases, contributing to its broad spectrum of activity. However, it is not effective against bacteria that produce carbapenemases, such as New Delhi metallo-beta-lactamase (NDM) or Klebsiella pneumoniae carbapenemase (KPC).

How has Ertapenem Sodium's Market Evolved Post-Patent Expiry?

The market for ertapenem sodium has undergone significant transformation following the expiry of its primary patents. Merck’s original brand, INVANZ®, faced robust generic competition, leading to substantial price erosion and a shift in market share towards generic manufacturers.

Key market evolution aspects:

• Generic Entry: The period following the expiry of Merck's core patents saw the introduction of multiple generic versions of ertapenem sodium. This increased competition directly impacted pricing.
• Price Compression: The presence of multiple generic competitors drove down the average selling price (ASP) of ertapenem sodium. This is a typical pattern in the pharmaceutical market after patent expiries, especially for established antibiotics.
• Market Share Shift: Generic manufacturers have captured a substantial portion of the ertapenem sodium market. This shift is driven by cost-effectiveness, particularly in hospital settings where formulary decisions are heavily influenced by price.
• Therapeutic Niche: Despite generic availability, ertapenem sodium retains its place as a valuable broad-spectrum antibiotic, particularly for specific indications where its efficacy and safety profile are well-established. It is often used when resistance to other antibiotic classes is suspected or confirmed.
• Competition within Carbapenems: Ertapenem sodium competes not only with its own generics but also with other carbapenems (e.g., meropenem, imipenem) and newer antibiotic classes that are being developed to address rising antimicrobial resistance.

The market for ertapenem sodium is characterized by high volume and lower per-unit margins for manufacturers compared to the branded product era. Generic manufacturers focus on efficient production and distribution to maintain profitability.

What are the Key Risk Factors Associated with Ertapenem Sodium?

Several risk factors are inherent to the market and therapeutic profile of ertapenem sodium, impacting its investment and commercial viability.

Key risk factors include:

• Antimicrobial Resistance: The increasing prevalence of carbapenem-resistant Enterobacteriaceae (CRE) and other carbapenemase-producing bacteria is a significant threat. Ertapenem sodium is ineffective against these resistant strains, limiting its utility and potentially leading to its displacement by newer agents or combination therapies. The World Health Organization (WHO) has identified carbapenem resistance as a critical global health threat [1].
• Generic Price Erosion: As a mature product with extensive generic competition, ertapenem sodium is subject to continuous price pressure. This limits revenue growth potential and necessitates highly efficient manufacturing and supply chain management for profitability.
• Competition from Newer Antibiotics: The development of novel antibiotics with different mechanisms of action or activity against resistant pathogens can displace older drugs like ertapenem sodium, especially in hospital settings where infection control protocols and treatment guidelines evolve rapidly.
• Off-Label Use and Stewardship: While approved for specific indications, ertapenem sodium may be used off-label. However, antimicrobial stewardship programs aim to optimize antibiotic use, potentially limiting the broad application of ertapenem sodium to cases where it is most clinically appropriate and effective, thereby reducing overall market volume.
• Manufacturing Complexity and Quality Control: The synthesis of carbapenem antibiotics is complex and requires stringent quality control to ensure purity and efficacy. Any manufacturing issues, supply chain disruptions, or quality control failures can lead to significant financial and reputational damage for manufacturers.
• Regulatory Scrutiny: Pharmaceutical products, especially antibiotics, are subject to ongoing regulatory oversight. Changes in prescribing guidelines, post-market surveillance requirements, or adverse event reporting can impact the market for ertapenem sodium.

What is the Competitive Landscape for Ertapenem Sodium?

The competitive landscape for ertapenem sodium is dominated by generic manufacturers, with the original innovator, Merck, maintaining a presence through its branded product and potential licensing agreements.

Key competitors and their strategies:

• Generic Manufacturers: A substantial number of generic pharmaceutical companies manufacture and market ertapenem sodium. These companies compete primarily on price, manufacturing efficiency, and market access. Examples include companies such as Teva Pharmaceutical Industries, Mylan N.V. (now part of Viatris), and various other global and regional generic players. Their strategy revolves around cost-effective production and aggressive tendering in hospital and institutional markets.
• Merck & Co., Inc. (Innovator): While the primary patent exclusivity has expired, Merck continues to market INVANZ®. Its strategy likely focuses on maintaining market share through established brand recognition, existing customer relationships, and potentially differentiating formulations or bundled services.
• Other Carbapenem Manufacturers: Ertapenem sodium competes indirectly with other carbapenems like meropenem and imipenem. These agents have different resistance profiles and pharmacokinetic properties, leading to distinct clinical niches. Manufacturers of these alternative carbapenems represent competitive pressure.
• Manufacturers of Novel Antibiotics: Companies developing and marketing new antibiotic classes, particularly those targeting multidrug-resistant organisms (MDROs), represent a growing competitive threat. These novel agents may offer advantages in efficacy against resistant strains or improved safety profiles, potentially leading to their adoption over ertapenem sodium in certain clinical scenarios.

The competitive environment is characterized by intense price competition among generic players and a constant need to adapt to evolving clinical guidelines and the emergence of new resistant pathogens.

What is the Future Outlook for Ertapenem Sodium?

The future outlook for ertapenem sodium is shaped by the persistent need for broad-spectrum antibiotics against a backdrop of increasing antimicrobial resistance.

Key future considerations:

• Continued Demand in Specific Niches: Ertapenem sodium is likely to retain a role in treating infections where its efficacy is well-established and resistance to carbapenems is not a primary concern. This includes certain types of complicated intra-abdominal and skin infections, particularly in regions where carbapenem resistance is less prevalent.
• Impact of Resistance Trends: The increasing global prevalence of carbapenemase-producing organisms will undoubtedly limit the use of ertapenem sodium. As resistance rates rise, clinicians will increasingly opt for alternative treatments or combination therapies. This trend will put downward pressure on the market volume and therapeutic relevance of ertapenem sodium.
• Role in Combination Therapies: While ertapenem sodium's effectiveness against carbapenemase producers is nil, it may continue to be a component in empirical therapy for mixed infections, where it covers susceptible Gram-positive and Gram-negative organisms, while other agents are added to cover potential resistant pathogens.
• Generic Market Dynamics: The generic market for ertapenem sodium will remain competitive, with price being the dominant factor. Manufacturers that can achieve high-volume, low-cost production will likely remain the primary suppliers.
• Geographic Variations: The market outlook will vary geographically. In regions with lower rates of carbapenem resistance, ertapenem sodium may maintain its market share for a longer period. Conversely, in regions with high CRE prevalence, its use will likely decline more rapidly.
• Potential for New Formulations or Delivery Methods: While less likely for a mature generic product, there is always a theoretical possibility of innovation in formulation or delivery that could offer some renewed advantage, although this would likely require significant R&D investment and face existing patent hurdles.

Overall, the market for ertapenem sodium is expected to be stable in certain established indications but will face increasing challenges from antimicrobial resistance and competition from newer agents. Its long-term future will depend on its continued utility in susceptible infections and its ability to remain cost-effective within a highly competitive generic landscape.

Key Takeaways

• Ertapenem sodium’s primary patents have expired, leading to significant generic competition and price erosion.
• The drug remains a broad-spectrum antibiotic effective against a wide range of bacteria but is rendered ineffective by carbapenemase-producing organisms.
• Antimicrobial resistance, particularly carbapenem resistance, is the most significant threat to the future utility and market for ertapenem sodium.
• The competitive landscape is dominated by generic manufacturers competing on price and efficiency.
• The future outlook for ertapenem sodium is characterized by continued demand in specific niches where resistance is not prevalent, but with a declining market share overall due to resistance trends and competition from newer antibiotics.

Frequently Asked Questions

1. What is the current global market size for ertapenem sodium?

Specific global market size figures for ertapenem sodium are proprietary and fluctuate due to competitive pricing and regional demand. However, the market is substantial, driven by its broad-spectrum use in moderate to severe infections, particularly within hospital settings. Generic penetration has increased the volume of units sold while decreasing overall revenue compared to the branded era.

2. Are there any ongoing patent litigations that could impact ertapenem sodium availability?

Ongoing patent litigations related to ertapenem sodium typically involve secondary patents covering specific manufacturing processes, crystal forms, or formulations. While the core compound patents have expired, these secondary patents can influence the timing and nature of generic entry or specific product claims. Such litigations can create temporary supply disruptions or exclusivity periods for specific generic versions.

3. How does ertapenem sodium compare to meropenem in terms of efficacy and resistance profiles?

Ertapenem sodium has a slightly narrower spectrum of activity compared to meropenem. Notably, ertapenem is less active against Pseudomonas aeruginosa and some other Gram-negative organisms compared to meropenem. Both are susceptible to carbapenemase-producing bacteria. Meropenem is often preferred for more severe infections or when P. aeruginosa is a suspected pathogen due to its broader Gram-negative coverage and better penetration into certain tissues.

4. What are the primary regulatory hurdles for manufacturers of ertapenem sodium generics?

Generic manufacturers face regulatory hurdles including demonstrating bioequivalence to the reference listed drug (INVANZ®), meeting stringent Good Manufacturing Practice (GMP) standards for drug substance and drug product manufacturing, and obtaining approval from regulatory authorities such as the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA). Post-market surveillance and pharmacovigilance are also ongoing requirements.

5. What are the key drivers for the continued use of ertapenem sodium despite rising resistance?

Continued use is driven by its established efficacy in treating susceptible bacterial infections, its broad spectrum covering many common pathogens, and its cost-effectiveness compared to some newer, more specialized antibiotics. In regions with lower rates of carbapenem resistance, it remains a first-line option for many indicated infections. Furthermore, empirical treatment guidelines often include carbapenems, and ertapenem can be a suitable choice when broader Gram-negative coverage is not strictly necessary and cost is a significant factor.

Citations

[1] World Health Organization. (2020). Antimicrobial resistance. Retrieved from https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance